Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Neurobo Pharmaceuticals stock

Learn how to easily invest in Neurobo Pharmaceuticals stock.

Neurobo Pharmaceuticals Inc is a biotechnology business based in the US. Neurobo Pharmaceuticals shares (NRBO) are listed on the NASDAQ and all prices are listed in US Dollars. Neurobo Pharmaceuticals employs 5 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Neurobo Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NRBO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Neurobo Pharmaceuticals stock price (NASDAQ: NRBO)

Use our graph to track the performance of NRBO stocks over time.

Neurobo Pharmaceuticals shares at a glance

Information last updated 2022-10-03.
Latest market close$13.26
52-week range$7.41 - $74.40
50-day moving average $13.29
200-day moving average $21.70
Wall St. target price$16.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.61

Buy Neurobo Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Neurobo Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Neurobo Pharmaceuticals price performance over time

Historical closes compared with the close of $13.26 from 2022-10-03

1 week (2022-09-28) -0.60%
1 month (2022-09-02) 4,233.33%
3 months (2022-07-05) 2,782.61%
6 months (2022-04-05) 1,389.89%
1 year (2021-10-05) 502.73%
2 years (2020-10-05) 129.41%
3 years (2019-10-04) 3,688.57%
5 years (2017-10-05) 31.55%

Neurobo Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -84.95%
Return on equity TTM -155.28%
Profit margin 0%
Book value $9.94
Market capitalisation $11.6 million

TTM: trailing 12 months

Neurobo Pharmaceuticals share dividends

We're not expecting Neurobo Pharmaceuticals to pay a dividend over the next 12 months.

Have Neurobo Pharmaceuticals's shares ever split?

Neurobo Pharmaceuticals's shares were split on a 1:30 basis on 13 September 2022. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Neurobo Pharmaceuticals shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Neurobo Pharmaceuticals shares which in turn could have impacted Neurobo Pharmaceuticals's share price.

Neurobo Pharmaceuticals share price volatility

Over the last 12 months, Neurobo Pharmaceuticals's shares have ranged in value from as little as $7.41 up to $74.4. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neurobo Pharmaceuticals's is -0.3814. This would suggest that Neurobo Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Neurobo Pharmaceuticals has bucked the trend.

Neurobo Pharmaceuticals overview

NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. It develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts. .

Frequently asked questions

What percentage of Neurobo Pharmaceuticals is owned by insiders or institutions?
Currently 29.866% of Neurobo Pharmaceuticals shares are held by insiders and 27.161% by institutions.
How many people work for Neurobo Pharmaceuticals?
Latest data suggests 5 work at Neurobo Pharmaceuticals.
When does the fiscal year end for Neurobo Pharmaceuticals?
Neurobo Pharmaceuticals's fiscal year ends in December.
Where is Neurobo Pharmaceuticals based?
Neurobo Pharmaceuticals's address is: 200 Berkeley Street, Boston, MA, United States, 02116
What is Neurobo Pharmaceuticals's ISIN number?
Neurobo Pharmaceuticals's international securities identification number is: US64132R1077
What is Neurobo Pharmaceuticals's CUSIP number?
Neurobo Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 36870A108

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site